Medical device company NeoVista, Inc., recently announced 12-month results from its MERITAGE study in patients with wet age-related macular degeneration, a leading cause of vision loss in older Americans.
The administration of the device plus the administration of as-needed anti-VEGF therapy is showing promising results.
The U.S. Food and Drug Administration has approved the first implantable eye telescope to improve vision in patients with end-stage age-related macular degeneration.
With the large Baby Boomer population reaching its senior years, the incidence of age-related vision loss in the U.S. is expected to increase.
Copyright © 2025 | WordPress Theme by MH Themes